Table 1 Characteristics of controls and PROTECT ulcerative colitis discovery and validation cohorts
Ctl (n = 20) RNAseq | UC (n = 428) Full PROTECT Cohort | UC (n = 206) RNAseq | UC mild (n = 54) RNAseq | UC mod-sev Discovery (n = 152) RNAseq | UC mod-sev Validation (n = 50) RNAseq | |
|---|---|---|---|---|---|---|
Age (Mean ± SD) | 13.9 ± 3.3 | 12.7 ± 3.3 | 12.9 ± 3.2 | 13.1 ± 3.5 | 12.8 ± 3.1 | 12.4 ± 3.4 |
Sex M (%) | 9 (45%) | 216 (50%) | 112 (54%) | 32 (59%) | 80 (53%) | 23 (46%) |
BMI z score (Mean ± SD) | 0.3 ± 1.6 | −0.2 ± 1.3 | −0.26 ± 1.32 | −0.08 ± 1.19 | −0.33 ± 1.36 | −0.28 ± 1.27 |
White | 17/20 (85%) | 351/420 (84%) | 204/206 (99%) | 52/54 (96%) | 152/152 (100%) | 28/50 (56%) |
PUCAI score (range 0–85) | ||||||
10–30 (Mild) | — | 102 (24%) | 54 (26%) | 54 (100%) | — | — |
35–60 (Moderate) | — | 185 (43%) | 84 (41%) | — | 83 (55%) | 21 (42%) |
≥65 (Severe) | — | 141 (33%) | 68 (33%) | — | 69 (45%) | 29 (58%) |
Mayo endoscopy subscore (range 0–3) | ||||||
Grade 1 Mild | — | 59 (14%) | 27 (13%) | 20 (37%) | 7 (5%) | 2 (4%) |
Grade 2 Moderate | — | 224 (52%) | 108 (52%) | 29 (54%) | 79 (52%) | 22 (44%) |
Grade 3 Severe | — | 145 (34%) | 71 (34%) | 5 (9%) | 66 (43%) | 26 (52%) |
Disease location | ||||||
Proctosigmoiditis | — | 29 (7%) | 14 (7%) | 11 (20%) | 3 (2%) | 0 (0%) |
Left-sided colitis | — | 44 (10%) | 25 (12%) | 14 (26%) | 11 (7%) | 1 (2%) |
Extensive/Pancolitis/a Unassessable | — | 355 (83%) | 167 (81%) | 29 (54%) | 138 (91%) | 49 (98%) |
Initial treatment | ||||||
Mesalamine | — | 136 (32%) | 53 (26%) | 53 (98%) | — | |
Oral or IV steroids | — | 292 (68%) | 153 (74%) | 1 (2%) | 152 (100%) | 50 (100%) |
Oral steroids | — | 144 (34%) | 82 (40%) | 1 (2%) | 81 (53%) | 20 (40%) |
IV steroids | — | 148 (34%) | 71 (34%) | — | 71 (47%) | 30 (60%) |
Week 4 remission (PUCAI < 10) | — | 211/422 (50)% | 105 (51%) | 30 (56%) | 75 (49%) | 21 (42%) |
Week 4 fecal calpro < 250 | — | 56/282 (20%) | 39/150 (26%) | 14/42 (33%) | 25/108 (23%) | 9/28 (32%) |
